Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TT5 in Healthy Participants and Surgical Patients
NCT06789861Phase 1Recruiting
- Sponsor
- Tafalgie Therapeutics
- Start
- May 2025
- Primary completion
- Oct 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain comparing TT5 with TT5 vehicle (2 arms). Primary endpoints: Incidence of Adverse Events and Serious Adverse Events, Clinically significant changes in physical examinations and 3 more. Started May 2025; status: recruiting.
02
Drugs
TT5
03
Conditions
pain
Beyond the preview
Go deeper on NCT06789861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06789861.